High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

Taking stock of the drug industry, from the lab to the medicine chest

January 17, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound Novo Nordisk has been facing pressure from investors to develop drugs that can deliver greater weight loss than those made by Eli Lilly. By Elaine Chen STAT+ | A reporter's JPM notebook: a look ahead for biopharma VC investing J.P. Morgan Healthcare Conference offers clues at what's next in biotech, pharma investments. VCs eye autoimmune disorders, bone density, new pain drugs. By Allison DeAngelis STAT+ | Medicare announces plan to negotiate prices of diabetes, weight loss drugs Weight loss drug on list of 15 whose prices will be negotiated under President Biden's Inflation Reduction Act. Also on the list: Trelegy Ellipta, Xtandi. By Rachel Cohrs Zhang Chris Knight/AP Paul Mango, Warp Speed leader and Trump adviser, dies at 65 Mango was instrumental to the effort to develop Covid-19 vaccines and treatments, and was working on the Trump transition effort. By Sarah Owermohle STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser